New therapies for treatment of rheumatoid arthritis

[1]  A. Dispenzieri.  Castleman disease. , 2008, Cancer treatment and research.

[2]  C. Dinarello,et al.  The biology of human interleukin-32 , 2007 .

[3]  P. Lipsky,et al.  Contemporary Targeted Therapies in Rheumatology , 2007 .

[4]  E. Keystone,et al.  Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. , 2007, Arthritis and rheumatism.

[5]  J. Smolen,et al.  Assessing remission in clinical practice. , 2007, Rheumatology.

[6]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[7]  I. McInnes,et al.  Emerging cytokine targets in rheumatoid arthritis , 2007, Current opinion in rheumatology.

[8]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[9]  M. Dougados,et al.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[10]  J. Kremer,et al.  Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial , 2006, Annals of the rheumatic diseases.

[11]  D. Kimpel,et al.  Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate , 2007 .

[12]  J. Smolen,et al.  What should be our treatment goal in rheumatoid arthritis today? , 2006, Clinical and experimental rheumatology.

[13]  A. Rowan,et al.  Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. , 2006, Arthritis and rheumatism.

[14]  Peter Nash,et al.  Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial , 2006, The Lancet.

[15]  P. Emery,et al.  Inhibiting toll-like receptors in inflammatory disease , 2006, The Lancet.

[16]  M. Weinblatt,et al.  Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. , 2006, Arthritis and rheumatism.

[17]  Michael M Ward,et al.  Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. , 2006, Arthritis and rheumatism.

[18]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[19]  J. Bluestone,et al.  Regulatory T‐cell physiology and application to treat autoimmunity , 2006, Immunological reviews.

[20]  T. Dorner,et al.  Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[21]  J. Browning.  B cells move to centre stage: novel opportunities for autoimmune disease treatment , 2006, Nature Reviews Drug Discovery.

[22]  H. Genant,et al.  Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.

[23]  W. Rifkin.  Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.

[24]  S. van der Linden,et al.  The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. , 2006, Arthritis and rheumatism.

[25]  P. Emery,et al.  Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[26]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[27]  J. Ware,et al.  Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. , 2006, The Journal of rheumatology.

[28]  F. Barkhof,et al.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.

[29]  John Han,et al.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.

[30]  T. Kano,et al.  Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[31]  A. Iliadou,et al.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[32]  M. Leandro,et al.  Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[33]  J. Smolen,et al.  The definition and measurement of disease modification in inflammatory rheumatic diseases. , 2006, Rheumatic diseases clinics of North America.

[34]  P. Emery.  Treatment of rheumatoid arthritis , 2006, BMJ : British Medical Journal.

[35]  Mahboob Rahman,et al.  One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: A phase II, randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006 .

[36]  B. Thiers.  Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition , 2006 .

[37]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[38]  Daniel Rodríguez‐Pinto.  B cells as antigen presenting cells. , 2005, Cellular immunology.

[39]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[40]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[41]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[42]  P. Parren,et al.  Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. , 2005, Arthritis and rheumatism.

[43]  Tanja Stamm,et al.  Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.

[44]  M. Dougados,et al.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[45]  M. Panzara,et al.  Natalizumab and progressive multifocal leukoencephalopathy. , 2005, The New England journal of medicine.

[46]  H. Mäkinen,et al.  Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? , 2005, Annals of the rheumatic diseases.

[47]  J. Zwerina,et al.  Pathogenesis of Rheumatoid Arthritis: Targeting Cytokines , 2005, Annals of the New York Academy of Sciences.

[48]  H. Heinzl,et al.  Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[49]  P. Tak,et al.  Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis , 2005, Expert opinion on emerging drugs.

[50]  G. Panayi.  B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? , 2005, Rheumatology.

[51]  D. M. van der Heijde,et al.  Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results , 2005, Annals of the rheumatic diseases.

[52]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[53]  R N Maini,et al.  Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. , 2005, Arthritis and rheumatism.

[54]  S. Rantapää-Dahlqvist.  Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis , 2005, Scandinavian journal of rheumatology.

[55]  I. Reid,et al.  Emerging and potential therapies for osteoporosis , 2005, Expert opinion on investigational drugs.

[56]  Iain B McInnes,et al.  Interleukin-18: a therapeutic target in rheumatoid arthritis? , 2004, Arthritis research & therapy.

[57]  E. Veys,et al.  Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis , 2004, Annals of the Rheumatic Diseases.

[58]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[59]  P. Emery,et al.  C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. , 2005, Arthritis and rheumatism.

[60]  M. Dougados,et al.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. , 2005, Annals of the rheumatic diseases.

[61]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[62]  E. Shevach.  Regulatory/suppressor T cells in health and disease. , 2004, Arthritis and rheumatism.

[63]  D. Isenberg,et al.  Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy , 2004, The Journal of experimental medicine.

[64]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[65]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[66]  A. A. Drosos,et al.  Epidemiology of rheumatoid arthritis. , 2004, Autoimmunity reviews.

[67]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[68]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[69]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[70]  B. Bresnihan.  Targeted Therapies in Rheumatology , 2004, Annals of Internal Medicine.

[71]  L. V. D. Putte,et al.  Patients with rheumatoid arthritis in clinical care , 2004 .

[72]  L. Klareskog,et al.  Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense , 2003, Annals of the rheumatic diseases.

[73]  M. Dougados,et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.

[74]  M. Weinblatt.  Rheumatoid arthritis in 2003: where are we now with treatment? , 2003, Annals of the rheumatic diseases.

[75]  T. Pincus,et al.  Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[76]  T. Pincus,et al.  A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. , 2003, Clinical and experimental rheumatology.

[77]  T. Kishimoto,et al.  Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.

[78]  J. Smolen,et al.  Therapeutic strategies for rheumatoid arthritis , 2003, Nature Reviews Drug Discovery.

[79]  R. Gay,et al.  Osteoclast-independent bone resorption by fibroblast-like cells , 2003, Arthritis Research & Therapy.

[80]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[81]  V. Strand,et al.  Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? , 2003, Arthritis and rheumatism.

[82]  P. Lipsky,et al.  Targeted Therapies in Rheumatology , 2002 .

[83]  R. Price,et al.  Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.

[84]  E. Wagner,et al.  HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc , 2002, Annals of the rheumatic diseases.

[85]  E. Keystone.  Treatments no longer in development for rheumatoid arthritis , 2002, Annals of the rheumatic diseases.

[86]  D. Isenberg,et al.  Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. , 2002, Rheumatology.

[87]  C. Walker,et al.  Toll-like receptors as potential therapeutic targets for multiple diseases , 2002, Nature Reviews Drug Discovery.

[88]  D. Miller,et al.  Health-related quality of life , 2002, Multiple sclerosis.

[89]  J. Smolen,et al.  Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. , 2002, The Journal of rheumatology.

[90]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[91]  Stanley B. Cohen,et al.  Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.

[92]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[93]  G. Kollias,et al.  Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. , 2002, Arthritis and rheumatism.

[94]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[95]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[96]  D. Maloney,et al.  Rituximab: Mechanism of action and resistance. , 2002, Seminars in oncology.

[97]  C. Thompson,et al.  Activation and inhibition of lymphocytes by costimulation. , 2002, The Journal of clinical investigation.

[98]  P. Johnson,et al.  Rituximab: mechanisms and applications , 2001, British Journal of Cancer.

[99]  Richard W. Martin,et al.  Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis. , 2001 .

[100]  M. Czuczman.  Combination chemotherapy and rituximab. , 2001, Anti-cancer drugs.

[101]  T. Kishimoto,et al.  Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. , 2001, Clinical immunology.

[102]  J. Edwards,et al.  Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. , 2001, Rheumatology.

[103]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[104]  M. Feldmann,et al.  The role of TNF alpha and IL-1 in rheumatoid arthritis. , 2001, Current directions in autoimmunity.

[105]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[106]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[107]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[108]  I. McInnes,et al.  A proinflammatory role for IL-18 in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[109]  G. Steiner,et al.  Cytokine production by synovial T cells in rheumatoid arthritis. , 1999, Rheumatology.

[110]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[111]  T. Kishimoto,et al.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. , 1998, Arthritis and rheumatism.

[112]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[113]  T. Thornhill,et al.  Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. , 1998, The American journal of pathology.

[114]  Jonathan M. Austyn,et al.  Dendritic cells , 1998, Current opinion in hematology.

[115]  D. Felson,et al.  ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials : Part 3: Rheumatoid Arthritis: Response , 1998 .

[116]  I. McInnes,et al.  Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis , 1997, Nature Medicine.

[117]  G. Firestein.  Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? , 1996, Arthritis and rheumatism.

[118]  J. Kriegsmann,et al.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. , 1996, The American journal of pathology.

[119]  M. Feldmann,et al.  Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2 , 1996, European journal of immunology.

[120]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[121]  J. Smolen.  Autoantibodies in rheumatoid arthritis , 1996 .

[122]  P. Emery,et al.  Early rheumatoid arthritis: time to aim for remission? , 1995, Annals of the rheumatic diseases.

[123]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[124]  M. Weinblatt.  Efficacy of methotrexate in rheumatoid arthritis. , 1995, British journal of rheumatology.

[125]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[126]  T. Pincus,et al.  Prediction of Long-Term Mortality in Patients with Rheumatoid Arthritis according to Simple Questionnaire and Joint Count Measures , 1994, Annals of Internal Medicine.

[127]  J. Kellum,et al.  Interleukin 6 , 1994, Critical care medicine.

[128]  T. Aune,et al.  Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines , 1993, Journal of leukocyte biology.

[129]  K. Yasukawa,et al.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. , 1993, Science.

[130]  P Tugwell,et al.  Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. , 1993, The Journal of rheumatology.

[131]  D. Wendling,et al.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. , 1993, The Journal of rheumatology.

[132]  M E Weinblatt,et al.  Methotrexate in rheumatoid arthritis. , 1988, Journal of the American Academy of Dermatology.

[133]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[134]  M. V. van Leeuwen,et al.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.

[135]  M. Feldmann,et al.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[136]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[137]  R. Maki,et al.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis. , 1990, Journal of immunology.

[138]  E. Clark,et al.  Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. , 1989, The Journal of biological chemistry.

[139]  D. Heijde,et al.  EFFECTS OF HYDROXYCHLOROQUINE AND SULPHASALAZINE ON PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[140]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[141]  W. Buurman,et al.  Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. , 1988, Journal of immunology.

[142]  J. Brown,et al.  Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.

[143]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[144]  H K Genant,et al.  How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? , 1985, Arthritis and rheumatism.

[145]  H. Genant.  Methods of assessing radiographic change in rheumatoid arthritis. , 1983, The American journal of medicine.

[146]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[147]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.

[148]  H. Cox,et al.  Letter: Moorgate tube disaster: disputed alcohol findings. , 1975, Lancet.

[149]  J. Moreland,et al.  Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. , 1971, Arthritis and rheumatism.

[150]  G. Felsch,et al.  [Autoantibodies in rheumatoid arthritis]. , 1968, Folia clinica internacional.